AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 272.11 USD | +0.99% |
|
+0.71% | +4.40% |
| Jan. 17 | Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks | MT |
| Jan. 17 | Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks | MT |
Summary: Amgen Inc.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: Amgen Inc.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses: Amgen Inc.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- One of the major weak points of the company is its financial situation.
- With a 2024 P/E ratio at 29.79 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings Chart: Amgen Inc.
Source: Surperformance
ESG chart: Amgen Inc.
Source: MSCI
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| 146B | |||||
| 653B | |||||
| 354B | |||||
| 353B | |||||
| 303B | |||||
| 248B | |||||
| 234B | |||||
| 207B | |||||
| 195B | |||||
| 149B | |||||
| Average | 284.21B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG MSCI
A
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
ESG
Environment
Social
Governance
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AMGN Stock
- Ratings Amgen Inc.